We are live on ! Find out more
VIA

Vident Investment Advisory Portfolio holdings

AUM $2.9B
1-Year Est. Return 24.67%
This Fund
S&P 500
This Quarter Est. Return
+4.64%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
–
AUM
$2.53B
AUM Growth
+$68.3M
Cap. Flow
+$49.5M
Cap. Flow %
1.96%
Top 10 Hldgs %
16.36%
Holding
1,009
New
121
Increased
515
Reduced
261
Closed
111

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$29.4M
2
AZTA icon
Azenta
AZTA
+$13.7M
3
FLIR
FLIR Systems, Inc. (DE) Common Stock
FLIR
+$13.2M
4
AMBA icon
Ambarella
AMBA
+$4.63M
5
TER icon
Teradyne
TER
+$3.54M

Top Sells

Rank Stock Value
1
OII icon
Oceaneering
OII
+$17.5M
2
ZBRA icon
Zebra Technologies
ZBRA
+$12.8M
3
ISRG icon
Intuitive Surgical
ISRG
+$11.2M
4
IPGP icon
IPG Photonics
IPGP
+$7.17M
5
IRBT
iRobot
IRBT
+$7.11M

Sector Composition

Rank Sector Weight
1 Technology 26.96%
2 Industrials 13.04%
3 Healthcare 11.78%
4 Consumer Discretionary 8.78%
5 Financials 6.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
976
Vertex Pharmaceuticals
VRTX
$126B
– –
-1,380
Closed -$219K
VTRS icon
977
Viatris
VTRS
$18.9B
– –
-5,092
Closed -$208K
VYX icon
978
NCR Voyix
VYX
$1.14B
– –
-10,800
Closed -$210K
WRB icon
979
W.R. Berkley
WRB
$26.6B
– –
-10,571
Closed -$233K
ZTS icon
980
Zoetis
ZTS
$30B
– –
-5,852
Closed -$494K
TXNM
981
TXNM Energy Inc
TXNM
$5.94B
– –
-7,708
Closed -$298K
PVLA
982
Palvella Therapeutics
PVLA
$2.27B
– –
-3,595
Closed -$1.86M
CNSL
983
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
– –
-15,395
Closed -$171K
LUMO
984
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-22,951
Closed -$858K
FSD
985
DELISTED
FIRST TRUST HIGH INCOME LONG/SHORT FUND
FSD
– –
-363,367
Closed -$5.5M
MDC
986
DELISTED
M.D.C. Holdings, Inc.
MDC
– –
-8,067
Closed -$202K
ACGN
987
DELISTED
Aceragen Inc
ACGN
– –
-6,471
Closed -$1.58M
LSI
988
DELISTED
Life Storage, Inc.
LSI
– –
-7,182
Closed -$414K
BLCM
989
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-20,526
Closed -$1.83M
JNCE
990
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-133,825
Closed -$2.75M
STOR
991
DELISTED
STORE Capital Corporation
STOR
– –
-12,714
Closed -$316K
AERI
992
DELISTED
Aerie Pharmaceuticals
AERI
– –
-10,304
Closed -$548K
CERN
993
DELISTED
Cerner Corp
CERN
– –
-7,574
Closed -$439K
CVA
994
DELISTED
Covanta Holding Corporation
CVA
– –
-18,869
Closed -$283K
XONE
995
DELISTED
The ExOne Company
XONE
– –
-277,348
Closed -$2.08M
MXIM
996
DELISTED
Maxim Integrated Products
MXIM
– –
-3,702
Closed -$215K
ALXN
997
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-3,780
Closed -$416K
TCO
998
DELISTED
Taubman Centers Inc.
TCO
– –
-6,282
Closed -$360K
CBL
999
DELISTED
CBL& Associates Properties, Inc.
CBL
– –
-12,875
Closed -$55K
CHSP
1000
DELISTED
Chesapeake Lodging Trust
CHSP
– –
-7,535
Closed -$220K
37 38 39
40
41

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
WI
Winder Investment Singapore $4.4B AUM 8.87% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return

Vident Investment Advisory's Q2 2018 Portfolio in Review

As of Q2 2018, Vident Investment Advisory held 1,009 positions worth $2.53B, up 2.8% from $2.46B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Vident Investment Advisory's Q2 2018 filing shows 121 new, 515 increased, 261 reduced and 111 closed positions. Its largest new stake was Arcus Biosciences: 156,139 shares worth $1.91M. The largest sale was Oceaneering, an estimated $17.5M.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Industrials and Healthcare.

  • Vident Investment Advisory's largest Q2 2018 buy was Arcus Biosciences: 156,139 shares worth $1.91M.
  • Vident Investment Advisory added most to State Street SPDR S&P 500 ETF Trust in Q2 2018, an estimated $29.4M increase.
  • Vident Investment Advisory's biggest Q2 2018 reduction was Oceaneering, cutting an estimated $17.5M.
  • Vident Investment Advisory fully exited FIRST TRUST HIGH INCOME LONG/SHORT FUND in Q2 2018, selling an estimated $5.5M.
  • Vident Investment Advisory's ten largest holdings make up 16% of its $2.53B portfolio in Q2 2018.
  • Vident Investment Advisory opened 121 new positions and closed 111 in Q2 2018.
  • Vident Investment Advisory's portfolio value rose 2.8% quarter-over-quarter to $2.53B.

Based on Vident Investment Advisory's 13F filing for Q2 2018, filed 14 Aug 2018.